查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887156

前列腺癌激素治疗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032 年）

Prostate Cancer Hormone Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

前列腺癌荷尔蒙治疗市场成长因素

随着前列腺癌发生率的持续上升和治疗创新技术的快速发展，全球前列腺癌激素治疗市场呈现强劲增长势头。根据最新的产业预测，该市场预计在 2024 年达到 160.7 亿美元，并在 2025 年达到 204.4 亿美元。预计到 2032 年，该市场规模将飙升至 799.3 亿美元，显示全球医疗保健系统对基于荷尔蒙疗法的治疗方案有着强劲的需求。 2024 年，北美地区凭藉先进的医疗保健基础设施、完善的报销政策以及对早期癌症诊断的高度重视，以 51.71% 的市场占有率占主导地位。

荷尔蒙疗法仍是前列腺癌治疗的基石。这种疗法也称为雄性激素剥夺疗法 (ADT)，它能降低驱动肿瘤生长的荷尔蒙水平，广泛用于转移性和晚期疾病的治疗。随着全球癌症负担的加重——2022 年全球癌症研究联盟 (GLOBOCAN 2022) 记录了 147 万例前列腺癌病例，使其成为第四大癌症发病原因——人们对荷尔蒙疗法作为核心治疗方法的依赖性日益增强。

市场驱动因素

先进荷尔蒙疗法的研发是推动市场发展的关键因素。各大製药公司正在推出新的雄性激素受体抑制剂和新一代基于促性腺激素释放激素 (GnRH) 的疗法，以克服抗药性并改善患者预后。 2023 年 11 月，安斯泰来製药和辉瑞的 XTANDI 获得 FDA 批准用于治疗非转移性去势敏感性前列腺癌，扩大了治疗选择的范围。

强大的研发管线和不断增加的临床试验持续加速治疗创新。 除了全球前列腺癌发生率不断上升外，已开发国家先进治疗手段的普及也支撑着市场的持续成长。

市场限制因子

一个主要的限制因素是对传统雄性激素剥夺疗法（ADT）抗药性的日益增强。随着时间的推移，前列腺癌细胞可能会发生突变，持续产生雄激素，从而降低治疗效果。例如，西尔维斯特综合癌症中心于2024年1月发表的一项研究表明，即使在激素抑制疗法期间，3β-羟基类固醇脱氢酶1（3BHSD1）也能使肿瘤再生雄激素，加速疾病进展。这种抗药性对治疗效果构成挑战，并限制了长期治疗的实施。

市场挑战

接受荷尔蒙治疗的患者常常会出现严重的副作用，这可能导致治疗顺从性下降。勃起功能障碍和性慾减退是常见的併发症。 2020 年 Elsevier 的一项研究发现，82% 的 ADT 患者出现勃起功能障碍，64% 的患者报告性慾下降，对生活​​品质有负面影响。这些不良反应仍然是治疗持续性的重大障碍。

市场机会

联合疗法具有巨大的未来潜力。製药公司正在积极探索 PARP 抑制剂与 ADT 的联合应用，以克服抗药性并延长存活期。 2025 年 2 月，TALAPRO-2 试验表明，他拉唑帕尼（Tarzena）和恩扎卢胺（Xtandi）的联合用药可使 HRR 缺陷型转移性前列腺癌患者的总生存期延长 14 个月，死亡风险降低 38%。 这些结果凸显了联合疗法在塑造未来治疗格局方面的巨大潜力。

市场区隔概览

依药物类别

2024年，GnRH激动剂凭藉其强大的睪固酮抑製作用占了最大的市场占有率。 CAMCEVI等产品的监管批准持续巩固了这个细分市场。由于多项新药核准和临床适应症的扩大，GnRH受体拮抗剂和雄激素受体抑制剂预计将显着成长。

依疾病类型

2024年，转移性去势抵抗性前列腺癌（mCRPC）细分市场引领市场，这主要得益于发病率的上升和获批标靶疗法数量的增加。 随着各公司扩大适应症范围，非转移性去势抵抗性前列腺癌 (CRPC) 市场预计将显着成长。

依给药途径

口服给药途径占最大占有率，这主要得益于其给药方便以及仿製药的普及（例如，Amneal 公司获得 FDA 批准的醋酸阿比特龙仿製药）。由于新的注射剂型正在研发中，肠外给药途径的市占率也持续成长。

按分销管道

医院药房占主导地位，这得益于医院拥有专业的癌症治疗中心，并且治疗过程由医生监督。 同时，随着药物可近性的提高，零售药局和线上药局也在稳定成长。

区域展望

北美

由于前列腺癌的高发病率和先进疗法的广泛应用，预计到2024年，北美市场规模将达到83.1亿美元。强大的研发基础和FDA的批准是该地区主导的重要因素。

欧洲

欧洲拥有第二大市场占有率，这得益于监管机构的批准。 2024年，NICE（英国国家卫生与临床优化研究所）推荐ORGOVYX作为经济有效的治疗选择。

亚太地区

由于人口老化和治疗药物核准数量的增加，预计亚太地区将实现最快成长。 2024年7月，中国国家药品监督管理局（NMPA）核准Estandi用于治疗转移性疾病。

拉丁美洲、中东和非洲

预计在合作不断扩大和前列腺癌治疗可及性逐步提高的推动下，该地区将实现温和增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 2024年主要国家及地区摄护腺癌盛行率
  • 主要公司产品线分析
  • 替代疗法概述
  • 市场主要新创企业
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 新冠疫情的影响市场

第五章：全球前列腺癌荷尔蒙治疗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 按药物类别划分
    • 雄性激素受体抑制剂
    • 促性腺激素释放激素 (GnRH) 激动剂
    • 促性腺激素释放激素 (GnRH) 受体拮抗剂
    • 其他
  • 市场分析、洞察与预测 - 按给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测 - 按疾病状态划分
    • 转移性去势抵抗性摄护腺癌
    • 非转移性去势抵抗性摄护腺癌癌症
  • 市场分析、洞察与预测 - 按销售管道划分
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美前列腺癌激素治疗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲前列腺癌激素治疗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区前列腺癌激素治疗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲前列腺癌激素治疗市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东和非洲前列腺癌激素疗法市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 安斯泰来药厂式会社
    • 辉瑞公司
    • 强生服务公司
    • 费林製药公司
    • 住友製药株式会社（Myovant Sciences） GmbH)
    • 艾伯维公司 (AbbVie Inc.)
    • 阿斯特捷利康 (AstraZeneca)
    • Accord BioPharma, Inc.
    • 拜耳股份公司 (Bayer AG)
Product Code: FBI112836

Growth Factors of prostate cancer hormone therapy Market

The global prostate cancer hormone therapy market is witnessing robust growth as prostate cancer prevalence continues to rise and treatment innovations advance rapidly. According to the latest industry estimates, the market was valued at USD 16.07 billion in 2024, is expected to reach USD 20.44 billion in 2025, and is projected to surge to USD 79.93 billion by 2032, demonstrating the strong demand for hormone-based treatment options across global healthcare systems. In 2024, North America dominated the market with a 51.71% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and high awareness of early cancer diagnosis.

Hormone therapy remains a cornerstone of prostate cancer management. Also known as Androgen Deprivation Therapy (ADT), this treatment reduces hormone levels that fuel tumor growth and is widely used in metastatic and advanced-stage cancers. With global cancer burden intensifying-GLOBOCAN 2022 recorded 1.47 million prostate cancer cases, making it the 4th most common cancer-there is rising dependence on hormone therapy as a core treatment approach.

Market Drivers

The development of advanced hormonal therapies is a major market driver. Leading pharmaceutical companies are introducing new androgen receptor inhibitors and next-generation GnRH-based therapies to overcome resistance and improve patient outcomes. In November 2023, Astellas Pharma and Pfizer received FDA approval for XTANDI for non-metastatic Castration-Sensitive Prostate Cancer, enabling broader treatment use.

Strong R&D pipelines and increasing clinical trials continue to accelerate therapeutic innovation. The rising global incidence of prostate cancer, coupled with expanding access to advanced therapies in developed nations, also supports continuous market growth.

Market Restraints

A significant restraint is the growing resistance to conventional ADT. Over time, prostate cancer cells may mutate and continue producing androgens, diminishing therapeutic effectiveness. For instance, research in January 2024 by Sylvester Comprehensive Cancer Center revealed that the enzyme 3BHSD1 enables tumors to regenerate androgens even during hormone suppression therapy, accelerating disease progression. This resistance challenges treatment efficacy and limits long-term therapy adoption.

Market Challenges

Patients undergoing hormonal therapy often experience substantial side effects, making treatment adherence challenging. Erectile dysfunction and libido loss are common complications. A study published by Elsevier in 2020 reported that 82% of ADT patients experienced erectile problems, while 64% reported loss of sexual desire, negatively affecting quality of life. Such adverse effects remain a major barrier to therapy continuation.

Market Opportunities

Combination therapies offer significant future opportunities. Pharmaceutical companies are increasingly exploring combinations of PARP inhibitors with ADT to address resistance and extend survival. In February 2025, the TALAPRO-2 trial demonstrated that combining talazoparib (Talzenna) with enzalutamide (Xtandi) provided a 14-month improvement in overall survival for HRR-deficient metastatic prostate cancer patients, with a 38% reduction in mortality risk. These outcomes highlight the strong potential of combination therapy in shaping the future treatment landscape.

Segmentation Overview

By Drug Class

In 2024, GnRH agonists held the leading share due to high effectiveness in testosterone suppression. Regulatory approvals for products like CAMCEVI continue strengthening this segment. GnRH receptor antagonists and androgen receptor inhibitors are expected to grow substantially due to multiple new approvals and expanded clinical indications.

By Disease State

The metastatic castration-resistant prostate cancer (mCRPC) segment dominated in 2024, driven by rising incidence and increased approvals of targeted therapies. The non-metastatic CRPC segment is set for strong growth as companies broaden their indications.

By Route of Administration

The oral segment held the largest share due to ease of administration and growing generic launches, such as Amneal's FDA-approved generic Abiraterone Acetate. The parenteral segment continues to expand with new injectable formulations under trial.

By Distribution Channel

Hospital pharmacies lead due to specialized cancer treatment centers and physician-supervised therapy administration. Retail and online pharmacies are growing steadily due to improved drug accessibility.

Regional Outlook

North America

The market reached USD 8.31 billion in 2024, driven by high prostate cancer incidence and advanced therapeutic adoption. Strong R&D presence and FDA approvals contribute to regional dominance.

Europe

Europe holds the second-largest share, supported by healthcare authority endorsements. In 2024, NICE recommended ORGOVYX as a cost-effective treatment option.

Asia Pacific

Expected to be the fastest-growing region due to rising aging populations and increasing therapy approvals. In July 2024, China's NMPA approved XTANDI for metastatic disease.

Latin America & Middle East/Africa

Moderate growth is expected, driven by rising collaborations and gradual improvements in prostate cancer treatment access.

Conclusion

The global prostate cancer hormone therapy market is on a strong growth trajectory, rising from USD 16.07 billion in 2024 to USD 20.44 billion in 2025, and projected to reach USD 79.93 billion by 2032. With expanding treatment innovations, increasing approvals, and strong R&D momentum, hormone therapy remains central to the future of prostate cancer care.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Disease State
    • 5.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Disease State
    • 6.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Disease State
    • 7.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Disease State
    • 8.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Disease State
    • 9.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Disease State
    • 10.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Ferring Pharmaceuticals Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. AbbVie Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AstraZeneca
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Accord BioPharma, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bayer AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 2: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 4: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 5: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 7: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 8: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 9: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 10: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 12: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 13: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 14: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 15: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 17: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 18: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 19: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 20: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 22: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 24: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 25: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 27: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 28: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 29: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
  • Table 30: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Prostate Cancer Hormone Therapy Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024 & 2032
  • Figure 3: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024 & 2032
  • Figure 5: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Prostate Cancer Hormone Therapy Market Value (USD billion), by Region, 2024 & 2032
  • Figure 7: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 8: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 9: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 10: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 11: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 12: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 13: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Prostate Cancer Hormone Therapy Market Value Share (%), By Country, 2024
  • Figure 17: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 18: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 19: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 20: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 21: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 22: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 23: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 28: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 29: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 30: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 31: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 32: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 33: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion),by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 38: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 39: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 40: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 41: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 42: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 43: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 48: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
  • Figure 49: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 50: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
  • Figure 51: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 52: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
  • Figure 53: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024

Figure 57: Global Prostate Cancer Hormone Therapy Market Share (%), By Company, 2024